Top 97 Contractors in PSC AN13: Health R&D Services; Health Care Services; Experimental Development, FY2022

Parent companies by net contract obligations Oct 1, 2021 – Sep 30, 2022 Code page on GovTribe

The top 10 won 68% of FY2022 PSC AN13 contract dollars

Ranking facts

Contract obligations
$683,286,475 Net of deobligations, by contracts coded PSC AN13
Contractors
100 Parent companies with an obligation
Largest contractor
Amgen Inc. $290 million, 31.4% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 97 rows as CSV

Full ranking

Rank Contractor Net obligations Share Trend
1 $290,059,904
Rank history: #71 in FY2021, #2 in FY2023 and not on the FY2024–FY2025 lists; up 70 since FY2021.
2 $94,290,582
Rank history: #20 in FY2021, #7 in FY2023 and not on the FY2024–FY2025 lists; up 18 since FY2021.
3 $53,621,288
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
4 $30,954,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
5 $30,191,062
Rank history: #22 in FY2021, #71 in FY2023, not on the FY2024 list and #12 in FY2025; up 17 since FY2021.
6 $29,432,278
Rank history: #1 in FY2021, #3 in FY2023, #2 in FY2024 and #2 in FY2025; down 5 since FY2021.
7 $28,108,045
Rank history: not on the FY2021 list, #17 in FY2023 and not on the FY2024–FY2025 lists; new.
8 $25,479,184
Rank history: #14 in FY2021, #68 in FY2023, #41 in FY2024 and not on the FY2025 list; up 6 since FY2021.
9 $22,429,401
Rank history: #21 in FY2021, #44 in FY2023 and not on the FY2024–FY2025 lists; up 12 since FY2021.
10 $22,424,287
Rank history: #18 in FY2021, #6 in FY2023 and not on the FY2024–FY2025 lists; up 8 since FY2021.
11 $18,412,068
Rank history: #43 in FY2021, #14 in FY2023 and not on the FY2024–FY2025 lists; up 32 since FY2021.
12 $16,555,952
Rank history: not on the FY2021 list, #13 in FY2023, #7 in FY2024 and #9 in FY2025; new.
13 $14,475,856
Rank history: #5 in FY2021, #9 in FY2023, #23 in FY2024 and not on the FY2025 list; down 8 since FY2021.
14 $13,827,499
Rank history: not on the FY2021 list, #36 in FY2023, #27 in FY2024 and not on the FY2025 list; new.
15 $12,900,000
Rank history: not on the FY2021 list, not on the FY2023 list, #12 in FY2024 and #44 in FY2025; new.
16 $11,015,838
Rank history: #9 in FY2021, #18 in FY2023, #14 in FY2024 and #4 in FY2025; down 7 since FY2021.
17 $10,877,462
Rank history: not on the FY2021 list, #48 in FY2023 and not on the FY2024–FY2025 lists; new.
18 $9,101,639
Rank history: not on the FY2021 list, #29 in FY2023, #28 in FY2024 and not on the FY2025 list; new.
19 $8,944,500
Rank history: not on the FY2021 list, #21 in FY2023 and not on the FY2024–FY2025 lists; new.
20 $8,528,240
Rank history: not on the FY2021 list, #32 in FY2023 and not on the FY2024–FY2025 lists; new.
21 $8,154,791
Rank history: #11 in FY2021, #27 in FY2023, #80 in FY2024 and #35 in FY2025; down 10 since FY2021.
22 $7,970,811
Rank history: #31 in FY2021, #46 in FY2023, #38 in FY2024 and #23 in FY2025; up 9 since FY2021.
23 $7,800,000
Rank history: not on the FY2021 list, #25 in FY2023, #19 in FY2024 and #34 in FY2025; new.
24 $6,900,669
Rank history: #19 in FY2021, #24 in FY2023, #18 in FY2024 and #32 in FY2025; down 5 since FY2021.
25 $6,240,948
Rank history: not on the FY2021 list, #28 in FY2023, #5 in FY2024 and #7 in FY2025; new.
26 $6,224,419
Rank history: not on the FY2021 list, not on the FY2023 list, #98 in FY2024 and not on the FY2025 list; new.
27 $6,144,230
Rank history: #10 in FY2021, not on the FY2023 list, #15 in FY2024 and not on the FY2025 list; down 17 since FY2021.
28 $5,989,293
Rank history: not on the FY2021 list, not on the FY2023 list, #39 in FY2024 and #67 in FY2025; new.
29 $5,955,427
Rank history: #52 in FY2021, #94 in FY2023, #25 in FY2024 and not on the FY2025 list; up 23 since FY2021.
30 $4,932,999
Rank history: #27 in FY2021 and not on the FY2023–FY2025 lists; down 3 since FY2021.
31
Guidehouse Inc.
$4,703,642
Rank history: not on the FY2021 list, #90 in FY2023 and not on the FY2024–FY2025 lists; new.
32
Diazyme Laboratories Inc.
$3,802,772
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
33 $3,800,000
Rank history: #70 in FY2021 and not on the FY2023–FY2025 lists; up 37 since FY2021.
34 $3,500,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
35 $3,195,203
Rank history: #36 in FY2021, #20 in FY2023 and not on the FY2024–FY2025 lists; up 1 since FY2021.
36 $3,157,000
Rank history: #28 in FY2021 and not on the FY2023–FY2025 lists; down 8 since FY2021.
37 $3,010,457
Rank history: #38 in FY2021, #66 in FY2023 and not on the FY2024–FY2025 lists; up 1 since FY2021.
38 $3,000,000
Rank history: #17 in FY2021 and not on the FY2023–FY2025 lists; down 21 since FY2021.
39 $2,923,902
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
40 $2,774,989
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #95 in FY2025; new.
41 $2,741,289
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
42 $2,634,246
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
43 $2,050,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
44 $2,000,000
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #79 in FY2025; new.
45 $2,000,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
46 $1,999,646
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
47 $1,999,386
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
48 $1,998,738
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
49 $1,988,212
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
50 $1,653,751
Rank history: #30 in FY2021, #30 in FY2023, not on the FY2024 list and #70 in FY2025; down 20 since FY2021.
51 $1,492,162
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #82 in FY2025; new.
52 $1,412,554
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
53 $1,218,705
Rank history: #6 in FY2021 and not on the FY2023–FY2025 lists; down 47 since FY2021.
54 $1,169,689
Rank history: not on the FY2021 list, #93 in FY2023, #45 in FY2024 and not on the FY2025 list; new.
55 $1,154,686
Rank history: not on the FY2021 list, #72 in FY2023, #47 in FY2024 and #75 in FY2025; new.
56
Albany Molecular Research Inc. Through Curia Global Inc.
$1,046,113
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
57 $975,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
58 $950,000
Rank history: #3 in FY2021 and not on the FY2023–FY2025 lists; down 55 since FY2021.
59 $876,312
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
60 $808,054
Rank history: not on the FY2021 list, #57 in FY2023 and not on the FY2024–FY2025 lists; new.
61
Oncotelic Therapeutics Inc. Through Oncotelic Inc.
$749,999
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
62 $749,999
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
63 $749,999
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
64 $749,999
Rank history: not on the FY2021 list, not on the FY2023 list, #9 in FY2024 and not on the FY2025 list; new.
65 $749,730
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
66 $749,676
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
67 $749,500
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
68 $749,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
69 $747,737
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
70 $745,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
71 $741,584
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
72 $704,293
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
73
Endpoint Health Inc
$679,115
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
74 $672,126
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
75 $649,383
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #68 in FY2025; new.
76 $645,622
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
77 $643,970
Rank history: not on the FY2021 list, #73 in FY2023 and not on the FY2024–FY2025 lists; new.
78 $636,081
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
79 $623,652
Rank history: #41 in FY2021, #91 in FY2023 and not on the FY2024–FY2025 lists; down 38 since FY2021.
80 $618,200
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
81 $473,104
Rank history: #15 in FY2021, #35 in FY2023, #22 in FY2024 and #16 in FY2025; down 66 since FY2021.
82 $381,930
Rank history: #68 in FY2021 and not on the FY2023–FY2025 lists; down 14 since FY2021.
83 $237,266
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
84 $163,125
Rank history: #2 in FY2021 and not on the FY2023–FY2025 lists; down 82 since FY2021.
85 $150,000
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
86 $142,144
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
87 $124,900
Rank history: #66 in FY2021 and not on the FY2023–FY2025 lists; down 21 since FY2021.
88 $113,773
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
89 $100,000
Rank history: not on the FY2021 list, not on the FY2023 list, #86 in FY2024 and #93 in FY2025; new.
90 $74,937
Rank history: #44 in FY2021, #65 in FY2023 and not on the FY2024–FY2025 lists; down 46 since FY2021.
91
Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek TNO
$74,492
Rank history: #59 in FY2021, #63 in FY2023 and not on the FY2024–FY2025 lists; down 32 since FY2021.
92 $63,377
Rank history: #60 in FY2021 and not on the FY2023–FY2025 lists; down 32 since FY2021.
93 $43,584
Rank history: not on the FY2021 list, #54 in FY2023, #79 in FY2024 and not on the FY2025 list; new.
94 $43,120
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
95 $20,478
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
96 $18,430
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
97
PPD Development LP
$2,245
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
Show 72 more

97 of 100 contractors listed here. See the rest on GovTribe.

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $925 million obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Fiscal year 2022 ran Oct 1, 2021 – Sep 30, 2022. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
  • Rank changes compare with FY2021. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2021 takes the color of the rank change beside it.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 PSC AN13 contractors in FY2022?

1. Amgen Inc. ($290M), 2. Mapp Biopharmaceutical, Inc. ($94.3M), 3. Laboratory Corporation of America Holdings ($53.6M), 4. Diasorin Molecular, LLC ($31M), 5. Abbott Laboratories ($30.2M), 6. Siga Technologies, Inc. ($29.4M), 7. Biofire Defense LLC ($28.1M), 8. Visby Medical, Inc. ($25.5M), 9. Hologic, Inc. ($22.4M), 10. Cerus Corporation ($22.4M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work